Catalyst Wire Dossier Catalyst Wire Dossier

Linagliptin (BI-1356)

linagliptin · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Linagliptin (BI-1356), covering 2012-10-26 to 2012-10-26. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study [Phase 3]

See pricing